Bristol Myers Squibb reports 2-year Psoriatic Arthritis data for Sotyktu
Bristol Myers Squibb said its Sotyktu (POETYK PsA-2 OLE) psoriatic arthritis results showed maintained efficacy and consistent safety through Week 104, with observed ACR20/50/70 responses of 76.9%/54.6%/37.7% and no new safety signals.
Bristol Myers Squibb said POETYK PsA-2 OLE results showed Sotyktu maintained efficacy and consistent safety through Week 104, with ACR20/50/70 responses up to 76.9%/54.6%/37.7% on an observed basis and no new safety signals.